VIPER

Registration Opens For The 2022 Safety In Action® Conference In Dallas

Retrieved on: 
Tuesday, February 22, 2022
Pressure, Conference, DEKRA, Health, Culture, Knowledge, Multimedia, Organization, Safety, VIPER, Management, Risk management

ATLANTA, Feb. 22, 2022 /PRNewswire/ -- The can't-miss conference for safety leaders at all levels is returning to Dallas on May 11 to 13, 2022.

Key Points: 
  • ATLANTA, Feb. 22, 2022 /PRNewswire/ -- The can't-miss conference for safety leaders at all levels is returning to Dallas on May 11 to 13, 2022.
  • DEKRA, a global leader in workplace safety and well-being, announced today that registration for the 2022 Safety in Action Conference is now open.
  • As the largest privately held front-line employee safety gathering in the world, the Safety in Action Conference is in its 35th year.
  • Register for the 2022 Safety in Action Conference , or fill out our interest form for further updates.

Deep Lens and Hematology-Oncology Associates of Central New York Collaborate to Improve Clinical Trial Matching for Oncology Patients

Retrieved on: 
Wednesday, January 12, 2022
Managed Care, Software, Research, Pharmaceutical, Data Management, Oncology, Technology, Hospitals, Clinical Trials, Science, Practice Management, Health, Other Science, National Cancer Institute, Patient, Technology, Nursing, Research, Foundation Medicine, Helmy Eltoukhy, Clinical trial, Lens, Adoption, Population, Therapy, Social, Pharmacist, VIPER, Diagnosis, Degenerative disease, Pathology, Cancer, EMR, Deep Lens Survey, CNY, Practitioner, Organization, Partnership, Pharmaceutical industry, Medical imaging, Medicine, Central New York, HOA, MD, Hematology-Oncology Associates of Central New York, Deep Lens, HEMATOLOGY-ONCOLOGY ASSOCIATES OF CENTRAL NEW YORK, DEEP LENS

Deep Lens and Hematology-Oncology Associates of Central New York (HOA CNY) today announced that they have entered into a collaboration to expand the clinical trial program and improve trial matching capabilities for the upstate New York-based practice.

Key Points: 
  • Deep Lens and Hematology-Oncology Associates of Central New York (HOA CNY) today announced that they have entered into a collaboration to expand the clinical trial program and improve trial matching capabilities for the upstate New York-based practice.
  • Deep Lens is a digital healthcare company that utilizes proprietary artificial intelligence-based technology solutions and other services to help improve efficiencies related to clinical trial recruitment and enrollment.
  • It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, fewer than 1 in 30 patients participate in a clinical trial.
  • Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.

Deep Lens and Ventura County Hematology Oncology Specialists Partner to Expand Clinical Trial Offering for Cancer Patients

Retrieved on: 
Friday, December 17, 2021
Managed Care, Software, Research, Pharmaceutical, Data Management, Oncology, Technology, Hospitals, Clinical Trials, Science, Practice Management, Health, Other Science, Database, Lens, NIH, Clinical trial, Physician, Diagnosis, Population, VIPER, Foundation Medicine, National, Helmy Eltoukhy, Cancer, Degenerative disease, NCI, Gibbs Cancer Center & Research Institute, Patient, Travel, Disease, Internal medicine, Pathology, Program, MD, Foundation for the National Institutes of Health, Oncology, National Cancer Institute, EMR, CA, Hematology, Technology, Medical imaging, Ventura County Hematology Oncology Specialists, Deep Lens, VENTURA COUNTY HEMATOLOGY ONCOLOGY SPECIALISTS, DEEP LENS

Deep Lens and Ventura County Hematology Oncology Specialists today announced that they have entered into a strategic agreement that will expand clinical trial opportunities for patients in the Ventura county area.

Key Points: 
  • Deep Lens and Ventura County Hematology Oncology Specialists today announced that they have entered into a strategic agreement that will expand clinical trial opportunities for patients in the Ventura county area.
  • As part of this collaboration, Ventura County Hematology Oncology Specialists will integrate Deep Lens artificial intelligence (AI) based clinical trial matching solution and other services to identify patients for trials faster and more effectively.
  • Ventura County Hematology Oncology Specialists is a comprehensive cancer center serving patients across Ventura and the surrounding coastal communities.
  • Deep Lens is a digital healthcare company that leverages AI to improve inefficiencies in the oncology clinical trial recruitment process.

VIPER™ Gaming Announces the VIPER VENOM DDR5 Performance Memory Kits

Retrieved on: 
Thursday, December 9, 2021
ECC, LED, SPD, CPU, Mouse, RGB, PATRIOT, DRAM, SSD, Intel, VP, DDR5, VENOM, PMIC, PCB, VIPER, Computer data storage

"The VIPER VENOM DDR5 is our first DDR5 DRAM customized for enthusiasts and hardcore gamers who might be obsessed with aggressive performance and reliability.

Key Points: 
  • "The VIPER VENOM DDR5 is our first DDR5 DRAM customized for enthusiasts and hardcore gamers who might be obsessed with aggressive performance and reliability.
  • VIPER VENOM RGB DDR5 modules come with the stylish VENOM heatshield design with a new design to combine the LED light bar and the heatshield.
  • The VIPER VENOM DDR5 Memory Series will be available Q1 2022 in major retailers worldwide with two packages with RGB and Non-RGB models.
  • VIPER is a trademarked brand of PATRIOT, a global leader in performance memory, SSD, and flash storage solutions.

Deep Lens Announces Launch of Real Time Feasibility Offering to Assist in Oncology Clinical Trial Design and Site Selection

Retrieved on: 
Tuesday, December 7, 2021
Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Physician, Precision medicine, EMR, CRO, Medicine, JAMA, Socialist Unity Network, Data analysis, Patient, Journal, Biomarker, American Medical Association, Cancer, Area studies, Lens, Vision, Clinical trial, Deep Lens Survey, Diagnosis, AI, VIPER, Medical imaging, Pharmaceutical industry, Deep Lens, Precision for Medicine, DEEP LENS, PRECISION FOR MEDICINE

Site selection is critical to ensuring on-time accrual; however, traditional feasibility studies rely on physicians estimating enrollment based on the number of patients seen in their clinical practice.

Key Points: 
  • Site selection is critical to ensuring on-time accrual; however, traditional feasibility studies rely on physicians estimating enrollment based on the number of patients seen in their clinical practice.
  • For more information about the Real Time Feasibility Offering or other Deep Lens services, please visit: www.deeplens.ai/real-time-feasibilty-dashboard .
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.
  • Precision applies novel biomarker approaches to clinical research that integrate clinical trial execution with deep scientific knowledge, laboratory expertise and advanced data sciences.

Deep Lens and Southern Oncology Specialists Enter Strategic Partnership That Will Use AI-Based Solution VIPER™ to Improve Clinical Trial Matching

Retrieved on: 
Thursday, October 28, 2021
Data Management, Other Health, Technology, Pharmaceutical, Physical Therapy, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Research, Technology, Diagnosis, Cancer, Disease, Innovation, ICOP, Pathology, CLIA, Partnership, Patient, Helmy Eltoukhy, VIPER, Foundation Medicine, Time, Precision medicine, Clinical trial, EMR, Population, Deep Lens Survey, Tempus, Medical imaging, Southern Oncology Specialists, Deep Lens, SOUTHERN ONCOLOGY SPECIALISTS, DEEP LENS

Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.

Key Points: 
  • Southern Oncology Specialists and Deep Lens today announced that they have entered into a strategic agreement that will use Deep Lens artificial intelligence (AI) based technology and other services to expand the practices clinical trial offering to patients.
  • Southern Oncology Specialists offers comprehensive cancer care and serves patients in four locations in the greater Charlotte region.
  • Deep Lens is a digital healthcare company that uses AI to accelerate clinical trial recruitment and enrollment for community oncology practices.
  • The Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.

Deep Lens and Ocala Oncology/Florida Cancer Affiliates Collaborate to Expand Clinical Research Program with AI-Based Trial Matching Solution

Retrieved on: 
Wednesday, October 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, Practice Management, Oncology, Managed Care, Hospitals, Clinical Trials, Science, Biotechnology, Software, Other Science, Health, Research, Clinical trial, Innovation, EMR, MD, Hematology, Diagnosis, Pathology, Research, Foundation Medicine, Patient, Partnership, Deep Lens Survey, Population, Cancer, ICOP, VIPER, Helmy Eltoukhy, Medical imaging, Ocala Oncology/Florida Cancer Affiliates, Deep Lens, OCALA ONCOLOGY/FLORIDA CANCER AFFILIATES, DEEP LENS

Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.

Key Points: 
  • Ocala Oncology/ Florida Cancer Affiliates and Deep Lens today announced that they have entered into a strategic agreement to expand the well-established clinical research program and offering to patients at the Ocala-based practice.
  • Ocala Oncology/Florida Cancer Affiliates specializes in hematology and oncology care and serves patients in the Central Florida area.
  • Deep Lens pre-screening and clinical trial matching solution is provided at no cost to oncology practices.
  • Deep Lens is a digital healthcare company focused on a groundbreaking approach to faster recruitment of the best-suited cancer patients to clinical trials.

DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates

Retrieved on: 
Tuesday, October 12, 2021
Private Securities Litigation Reform Act, Company, Forward-looking statement, Brain, Therapy, SMARCA2, Algorithm, Columbia University, Doctor of Philosophy, MCL1, Department, PRMT5, Drug discovery, Biotechnology, COVID-19, Biology, Protein, Goal, British Journal of Haematology, Drug development, GBM, Cancer, Drug combination, CDK9, Glioblastoma, MD, U.S. Securities and Exchange Commission, Security (finance), CEO, BEST, Solution, VIPER, Biomarker, Neoplasm, Overalls, Patient, Multiple myeloma, Technology, Risk, DLBCL, Systems biology, Medical imaging, Pharmaceutical industry, Fine chemical

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.

Key Points: 
  • NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.
  • Additionally, the collaboration will mechanistically characterize potential therapeutic opportunities for Prelude's pipeline molecules targeting various oncogenic pathways across multiple hematologic malignancies and solid tumor subtypes, as selected by Prelude Therapeutics.
  • As part of the BEST initiative, DarwinHealth will provide a comprehensive readout of the potential clinical value of select Prelude pipeline moleculesacross a spectrum of tumor types.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.

DarwinHealth Announces Scientific Collaboration with Prelude Therapeutics to Develop Novel Biomarkers for Multiple Oncology Candidates

Retrieved on: 
Tuesday, October 12, 2021
Private Securities Litigation Reform Act, Company, Forward-looking statement, Brain, Technology, Therapy, SMARCA2, Algorithm, Columbia University, Doctor of Philosophy, MCL1, Department, PRMT5, Drug discovery, Biotechnology, COVID-19, Biology, Protein, Goal, British Journal of Haematology, Drug development, GBM, Multimedia, Cancer, Drug combination, CDK9, Glioblastoma, MD, U.S. Securities and Exchange Commission, Security (finance), CEO, BEST, Solution, VIPER, Biomarker, Neoplasm, Overalls, Patient, Multiple myeloma, View, Risk, DLBCL, Systems biology, Medical imaging, Pharmaceutical industry, Fine chemical

NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.

Key Points: 
  • NEW YORK, Oct. 12, 2021 /PRNewswire/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being developed by Prelude Therapeutics.
  • Additionally, the collaboration will mechanistically characterize potential therapeutic opportunities for Prelude's pipeline molecules targeting various oncogenic pathways across multiple hematologic malignancies and solid tumor subtypes, as selected by Prelude Therapeutics.
  • As part of the BEST initiative, DarwinHealth will provide a comprehensive readout of the potential clinical value of select Prelude pipeline moleculesacross a spectrum of tumor types.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.

Deep Lens and Pacific Cancer Care Enter Strategic Partnership to Improve Clinical Trial Matching for Oncology Patients

Retrieved on: 
Friday, October 8, 2021
Software, Oncology, General Health, Health, Data Management, Technology, Genetics, Clinical Trials, University of California, Davis, Hematology, Acceleration, UCSF, Time, Diagnosis, Stanford University, Cancer, Dana–Farber Cancer Institute, Population, Helmy Eltoukhy, UC, Foundation Medicine, Central Coast (California), Deep Lens Survey, Pathology, Knowledge, Solution, VIPER, EMR, Partnership, Clinical trial, Patient, Disease, Medical imaging, Pharmaceutical industry, Pacific Cancer Care, Deep Lens, PACIFIC CANCER CARE, DEEP LENS

Pacific Cancer Care and Deep Lens today announced that they are collaborating to optimize clinical trial matching and accelerate enrollment at the Monterey-based practice through the use of Deep Lens artificial-intelligence (AI) based solutions and other services.

Key Points: 
  • Pacific Cancer Care and Deep Lens today announced that they are collaborating to optimize clinical trial matching and accelerate enrollment at the Monterey-based practice through the use of Deep Lens artificial-intelligence (AI) based solutions and other services.
  • This partnership will expand Pacific Cancer Cares existing clinical trial offering to patients by more accurately and effectively identifying eligible patients for trials, improving communications between patient care teams and bringing more trials to the practice.
  • It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, fewer than 1 in 30 patients participate in a clinical trial.
  • Pacific Cancer Care has provided superior care for patients, including innovative state of the art clinical trials, for nearly 50 years.